Senior Staff

Dr. Yoram Devary
Dr. Yoram DevaryFounder, Chairman and CTO

Dr. Devary is responsible for the Nerofe’ technology and Research & Development activities. He is an expert in the molecular mechanisms by which physical and chemical agents transform cells and has published groundbreaking findings relating to the cause of cancer. He serves as a scientific advisory to BI Solutions, an early-stage bioinformatics company. Dr. Devary holds a Ph.D. degree in Biotechnology from the University of California, San Diego (UCSD). Dr Devary published several papers in distinguished journal such as Cell and Science.

Dr. Yoram Devary
Dr. Yoram Devary
Founder, Chairman and CTO
Dr. Devary is responsible for the Nerofe’ technology and Research & Development activities. He is an expert in the molecular mechanisms by which physical and chemical agents transform cells and has published groundbreaking findings relating to the cause of cancer. He serves as a scientific advisory to BI Solutions, an early-stage bioinformatics company. Dr. Devary holds a Ph.D. degree in Biotechnology from the University of California, San Diego (UCSD). Dr Devary published several papers in distinguished journal such as Cell and Science.
Prof. Uziel Sandler
Prof. Uziel SandlerFounder, Vice-Chairman and CEO

Professor Uziel Sandler are one of the founders of the advanced discipline called “Fuzzy Dynamics”, which describes evolution of complex systems with uncertainty in their dynamics laws. Fuzzy Dynamics has been successfully applied to modeling of immune system cells maturation and neural cells behavior. Uziel Sandler is also an expert in DNA and Macromolecular Dynamics and Evolutionary Computations. He has published more than 80 academic articles in prestigious scientific journals and three books among which “Neural Cell Behavior and Fuzzy Logic”, Springer, NY, 2008. Prof. Sandler has served as chair in international conferences and as a member in several worldwide committees in the above-mentioned fields. Prof. Sandler holds a Ph.D. in Theoretical Physics from L.V. Kirensky Institute of Physics, Academy of Science, of the former USSR.

Prof. Uziel Sandler
Prof. Uziel Sandler
Founder, Vice-Chairman and CEO
Professor Uziel Sandler are one of the founders of the advanced discipline called “Fuzzy Dynamics”, which describes evolution of complex systems with uncertainty in their dynamics laws. Fuzzy Dynamics has been successfully applied to modeling of immune system cells maturation and neural cells behavior. Uziel Sandler is also an expert in DNA and Macromolecular Dynamics and Evolutionary Computations. He has published more than 80 academic articles in prestigious scientific journals and three books among which “Neural Cell Behavior and Fuzzy Logic”, Springer, NY, 2008. Prof. Sandler has served as chair in international conferences and as a member in several worldwide committees in the above-mentioned fields. Prof. Sandler holds a Ph.D. in Theoretical Physics from L.V. Kirensky Institute of Physics, Academy of Science, of the former USSR.

Advisory Board

Prof. Joseph D Rosenblatt
Prof. Joseph D Rosenblatt

Joseph D Rosenblatt is Professor of Medicine, Microbiology and Immmunology at the University of Miami Miller School of Medicine , and currently serves as the William Harrington Professor of Hematology and Chief of the University of Miami Division of Hematology.
He previously served as chief of the combined Division of Hematology – Oncology from 2001-2017, when Hematology became a separate Division. Rosenblatt also currently serves as Associate Director for Faculty Development in the Sylvester Comprehensive Cancer Center and previously served as Interim Director of the Sylvester Comprehensive Cancer Center from 2010-2012. From 2001 -2017 he served as Associate Director for Clinical and Translational Research within the Sylvester Comprehensive Cancer Center.
Dr. Rosenblatt joined UM/Sylvester in September 2001 from the University of Rochester where he served as the Chief of the Hematology-Oncology Unit and Associate Director for Clinical Research at the James P. Wilmot Cancer Center from 1995-2001. He completed Medical School, Residency and Hematology –Oncology fellowship training at the University of California at Los Angeles , where he joined the faculty rising to the rank of Associate Professor.
Professor Rosenblatt is well known for research in the areas of human retroviruses, immune therapies for cancer, human gene therapy and antibody engineering has been a principal investigator on numerous grants from the National Institutes of Health, US Department of Defense, American Cancer Society and the Leukemia and Lymphoma Society of America.
He is a former member of National Cancer Institute Experimental Therapeutics II, and Clinical Immunology and Immunotherapy study sections, and has been a three time and current member of the international Israel Cancer Research Fund Scientific Review Panel.
DR Rosenblatt maintains an active clinical practice focused on lymphoid and other hematologic malignancies and has served as Principal Investigator on multiple clinical trials. Rosenblatt has served on scientific advisory panels for Merck, Seattle Genetics, Kite among others and most recently for Synergys – a biotechnology startup. He recently has been an academic co-investigator on two NCI SBIR grants.

Prof. Joseph D Rosenblatt
Prof. Joseph D Rosenblatt
Joseph D Rosenblatt is Professor of Medicine, Microbiology and Immmunology at the University of Miami Miller School of Medicine , and currently serves as the William Harrington Professor of Hematology and Chief of the University of Miami Division of Hematology.
He previously served as chief of the combined Division of Hematology – Oncology from 2001-2017, when Hematology became a separate Division. Rosenblatt also currently serves as Associate Director for Faculty Development in the Sylvester Comprehensive Cancer Center and previously served as Interim Director of the Sylvester Comprehensive Cancer Center from 2010-2012. From 2001 -2017 he served as Associate Director for Clinical and Translational Research within the Sylvester Comprehensive Cancer Center.
Dr. Rosenblatt joined UM/Sylvester in September 2001 from the University of Rochester where he served as the Chief of the Hematology-Oncology Unit and Associate Director for Clinical Research at the James P. Wilmot Cancer Center from 1995-2001. He completed Medical School, Residency and Hematology –Oncology fellowship training at the University of California at Los Angeles , where he joined the faculty rising to the rank of Associate Professor.
Professor Rosenblatt is well known for research in the areas of human retroviruses, immune therapies for cancer, human gene therapy and antibody engineering has been a principal investigator on numerous grants from the National Institutes of Health, US Department of Defense, American Cancer Society and the Leukemia and Lymphoma Society of America.
He is a former member of National Cancer Institute Experimental Therapeutics II, and Clinical Immunology and Immunotherapy study sections, and has been a three time and current member of the international Israel Cancer Research Fund Scientific Review Panel.
DR Rosenblatt maintains an active clinical practice focused on lymphoid and other hematologic malignancies and has served as Principal Investigator on multiple clinical trials. Rosenblatt has served on scientific advisory panels for Merck, Seattle Genetics, Kite among others and most recently for Synergys – a biotechnology startup. He recently has been an academic co-investigator on two NCI SBIR grants.
Mr. Bruno Pagliara

Has over 30 years experience in International Pharmaceutical Marketing and Business Development held at international headquarter locations and has a successful track record in marketing, strategic planning and building businesses through business development and licensing, in the specialty pharmaceutical and oncology areas. From 1999 to 2007 Bruno was VP Corporate Development of Chiesi Pharmaceuticals, a privately held European multinationals pharmaceutical. During this period he finalized more than 15 major transactions. Mr. Pagliara managed a business of over $400M, launched epirubicin and idarubicin on a global basis, worked on the line extensions of doxorubicin increasing the business by over $80M pa, launched medroxyprogesterone acetate in breast cancer, a global business of about $100M, nicergoline and anti biotics in several countries.

Mr. Bruno Pagliara
Mr. Bruno Pagliara
Has over 30 years experience in International Pharmaceutical Marketing and Business Development held at international headquarter locations and has a successful track record in marketing, strategic planning and building businesses through business development and licensing, in the specialty pharmaceutical and oncology areas. From 1999 to 2007 Bruno was VP Corporate Development of Chiesi Pharmaceuticals, a privately held European multinationals pharmaceutical. During this period he finalized more than 15 major transactions. Mr. Pagliara managed a business of over $400M, launched epirubicin and idarubicin on a global basis, worked on the line extensions of doxorubicin increasing the business by over $80M pa, launched medroxyprogesterone acetate in breast cancer, a global business of about $100M, nicergoline and anti biotics in several countries.
Dr. Dov Kanner, Ph.D.

Has served since 2005 as CEO of Bio-Technology General (Israel) Ltd. (BTG), a wholly owned subsidiary of Ferring Holding SA of Switzerland. Dr. Kanner has a wide experience as an executive in biopharma drug development at BTG since 1981, including Head of Fermentation from 1984 to 1989, Deputy Director, Manufacturing and Process Development from 1989 to 1994, and Vice President, Quality Assurance and Regulatory Affairs from 1994 to 2000. In 2000 he was appointed Senior Vice President of Savient Pharmaceuticals Inc. and Managing Director of BTG Ltd., in 2003, Executive Vice President, Chief Technical Officer of Savient while continuing as Managing Director of BTG Ltd. Dr. Kanner holds a Ph.D. degree in Microbiology from Rutgers University.

Dr. Dov Kanner, Ph.D.
Dr. Dov Kanner, Ph.D.
Has served since 2005 as CEO of Bio-Technology General (Israel) Ltd. (BTG), a wholly owned subsidiary of Ferring Holding SA of Switzerland. Dr. Kanner has a wide experience as an executive in biopharma drug development at BTG since 1981, including Head of Fermentation from 1984 to 1989, Deputy Director, Manufacturing and Process Development from 1989 to 1994, and Vice President, Quality Assurance and Regulatory Affairs from 1994 to 2000. In 2000 he was appointed Senior Vice President of Savient Pharmaceuticals Inc. and Managing Director of BTG Ltd., in 2003, Executive Vice President, Chief Technical Officer of Savient while continuing as Managing Director of BTG Ltd. Dr. Kanner holds a Ph.D. degree in Microbiology from Rutgers University.
Prof.Moshe Mittelman, M.D

Prof. Mittelman is recognized, licenced expert in internal medicine; general hematology, leukemia, preleukemia and multiple myeloma (blood cancer). He serves as Chairman of Department of Medicine, Tel Aviv Sourasky Medical Center. Moshe Mittelman has published more than 144 papers, in both clinical and research fields, most of them in the areas of internal medicine, blood and cancer diseases. He is a member of the editorial board of “European Journal of Internal Medicine” and ad hoc reviewer for several international journals, among them “Annals of Hematology”, “British Journal of Hematology”, “European Journal of Hematology”, “Drugs” and others. Prof. Mittelman holds a M.D. degree from Tel Aviv University, Sackler School of Medicine.

Prof.Moshe Mittelman, M.D
Prof.Moshe Mittelman, M.D
Prof. Mittelman is recognized, licenced expert in internal medicine; general hematology, leukemia, preleukemia and multiple myeloma (blood cancer). He serves as Chairman of Department of Medicine, Tel Aviv Sourasky Medical Center. Moshe Mittelman has published more than 144 papers, in both clinical and research fields, most of them in the areas of internal medicine, blood and cancer diseases. He is a member of the editorial board of “European Journal of Internal Medicine” and ad hoc reviewer for several international journals, among them “Annals of Hematology”, “British Journal of Hematology”, “European Journal of Hematology”, “Drugs” and others. Prof. Mittelman holds a M.D. degree from Tel Aviv University, Sackler School of Medicine.
Dr. Baruch Berliner, PhD

Dr. Berliner is world recognized expert in finance management and risk insurability. He wrote several books among which “Limits of Insurability of Risks, Prentice-Hall, 1982”, which was published in English, German, Italian and Spanish. Dr. Berliner has served as Senior Research associate and Chairman of Scientific Committee, Erhard Insurance Center, Faculty of Management of the Tel-Aviv University. He has also served as non-life actuary and assistant manager in Swiss Reinsurance Company, Zurich, Switzerland. Since 1978, Dr.Berliner has been acting as a judge for the Berliner Prize, and since 1984 for the Gottlieb Prize. Dr. Berliner holds a Ph.D. degree in Mathematical Statistics from University of Zurich, Switzerland.

Dr. Baruch Berliner, PhD
Dr. Baruch Berliner, PhD
Dr. Berliner is world recognized expert in finance management and risk insurability. He wrote several books among which “Limits of Insurability of Risks, Prentice-Hall, 1982”, which was published in English, German, Italian and Spanish. Dr. Berliner has served as Senior Research associate and Chairman of Scientific Committee, Erhard Insurance Center, Faculty of Management of the Tel-Aviv University. He has also served as non-life actuary and assistant manager in Swiss Reinsurance Company, Zurich, Switzerland. Since 1978, Dr.Berliner has been acting as a judge for the Berliner Prize, and since 1984 for the Gottlieb Prize. Dr. Berliner holds a Ph.D. degree in Mathematical Statistics from University of Zurich, Switzerland.